Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;27(5):637-642.
doi: 10.1007/s40291-023-00662-1. Epub 2023 Jun 24.

Omidubicel: First Approval

Young-A Heo  1
Affiliations
Review

Omidubicel: First Approval

Young-A Heo. Mol Diagn Ther. 2023 Sep.

Abstract

Omidubicel (omidubicel-onlv; Omisirge®) is a nicotinamide-modified stem cell graft derived from cord blood that is being developed by Gamida Cell for the treatment of haematological malignancies and haemoglobinopathies. In April 2023, omidubicel received its first approval in the USA for use in adults and children aged ≥ 12 years with haematological malignancies who are planned for cord blood transplantation following myeloablative conditioning to reduce the incidence of infection and the time to neutrophil recovery. This article summarizes the milestones in the development of omidubicel leading to this first approval.

PubMed Disclaimer

References

    1. Lin C, Schwarzbach A, Sanz J, et al. Multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with omidubicel: a pooled analysis of five prospective clinical trials. Transplant Cell Ther. 2023;29(5):338.e1-e6. - DOI - PubMed
    1. Saiyin T, Kirkham AM, Bailey AJM, et al. Clinical outcomes of umbilical cord blood transplantation using ex vivo expansion: a systematic review and meta-analysis of controlled studies. Transplant Cell Ther. 2023;29(2):129.e1-e9. - DOI
    1. Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429–40. - DOI - PubMed - PMC
    1. Gamida Cell. Gamida Cell announces FDA acceptance of Biologics License application for omidubicel with Priority Review [media release]. 1 Aug 2022. http://www.gamida-cell.com .
    1. US Food & Drug Administration. FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation [media release]. 17 Apr 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-cell-th... .

LinkOut - more resources